Compare ERH & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ERH | FBIO |
|---|---|---|
| Founded | 2004 | 2006 |
| Country | United States | United States |
| Employees | N/A | 101 |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.7M | 104.6M |
| IPO Year | N/A | N/A |
| Metric | ERH | FBIO |
|---|---|---|
| Price | $12.42 | $2.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 20.3K | ★ 423.1K |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | ★ 8.85% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $29.71 |
| Revenue Next Year | N/A | $49.34 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.98 | $1.33 |
| 52 Week High | $13.07 | $4.53 |
| Indicator | ERH | FBIO |
|---|---|---|
| Relative Strength Index (RSI) | 59.43 | 34.58 |
| Support Level | $11.59 | $2.47 |
| Resistance Level | $12.53 | $2.71 |
| Average True Range (ATR) | 0.19 | 0.18 |
| MACD | 0.03 | -0.04 |
| Stochastic Oscillator | 88.10 | 22.75 |
Allspring Utilities and High Income Fund is a diversified closed-end management investment company. Its investment objective is to seek a high level of current income and moderate capital growth, with an emphasis on providing tax-advantaged dividend income. The company allocates a majority of its total assets to a sleeve that places a focus on common, preferred, and convertible preferred stocks of utility companies and the rest of its total assets to a sleeve of U.S. dollar denominated below investment grade (high yield) debt.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.